Logo

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Share this

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Shots:

  • TetraGenetics to receive $25M upfront- $248M milestones as contingent payments- FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders
  • The focus of the agreement is to develop non-opioid therapies with advancement of mAbs targeting ion channels utilizing TetraExpress technology for the treatment of pain conditions
  • TetraExpress technology is an Ab discovery platform for developing biologics targeting ion channel for autoimmune diseases and pain

Ref: Imbrium Therapeutics | Image: MassBio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions